Faeth Therapeutics (FTH) Analyst Consensus at $61: Assessing the Path to +381% Upside

Key Takeaways

• The central target of $61 is the arithmetic mean of the four most recent, individually verifiable analyst price targets reviewed, rounded from a calculated mean of roughly $60.75.
• At a latest price near $12.68, reaching $61 would require a gain of roughly 381% — a very large move even by clinical-stage biotech standards.
• The target is drawn from a wider analyst field: data providers tracking roughly 15 to 17 analysts show individual targets spanning approximately $40 to $70.
• The strongest supporting factor is recent Phase 2 PIK-201 data in endometrial cancer, which several analysts argue was sold off disproportionately.
• The biggest risks are binary clinical outcomes, no product revenue, heavy cash burn, and potential shareholder dilution.
• For more on this company, explore its Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

Faeth Therapeutics, Inc. (FTH) is a clinical-stage oncology biotechnology company — formerly Sensei Biotherapeutics — developing PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor, for endometrial and breast cancer, along with the VISTA-targeting antibody Solnerstotug. As a stock with active sell-side coverage, it carries genuine analyst price targets, though the post-data volatility has left the field unusually wide.

Four recent targets could be attributed to named firms and dates: BTIG at $55 (November 9, 2026), Lucid Capital at $59 (November 9, 2026), H.C. Wainwright at $60 (November 9, 2026), and Guggenheim at $69 (revised from $70 on November 4, 2026). Their arithmetic mean of $60.75 rounds to the $61 central target used here. Broader data providers tracking roughly 15 to 17 analysts report a wider band of about $40 to $70, with most recent actions clustered in the mid-to-high $50s and $60s.

Views are almost uniformly bullish, but the reasoning differs. Bulls emphasize durable disease control and manageable toxicity; more cautious analysts flag that the headline response rate merely matches — rather than clearly beats — emerging antibody-drug conjugates (ADCs). That divergence explains the unusually wide range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Shares last traded near $12.68, down roughly 42% in a single session after topline Phase 2 PIK-201 results in advanced PAM-pathway-altered endometrioid endometrial cancer. The stock fell as low as about $10.45 intraday, its weakest level since just before the reverse merger that created the current entity. The 52-week range spans $7.45 to $42.14, with a market capitalization of roughly $328 million.

From $12.68, reaching $61 implies upside of about 381% — a very large move. For a pre-revenue biotech, the realistic path is event-driven rather than gradual: successive positive readouts on PIKTOR's breast cancer program, successful regulatory engagement, and progress toward pivotal trials would each need to re-rate the shares meaningfully. No single quarter's fundamentals can bridge a gap this wide.

What Could Support a Move Toward the Target

The Phase 2 PIK-201 trial reported a 33% confirmed objective response rate (ORR) in 36 efficacy-evaluable patients, an 83% disease control rate, and a preliminary median progression-free survival (PFS) of about 7.4 months — well above the roughly three-to-four-month benchmark of contemporary salvage chemotherapy. Several analysts called the selloff "overdone" or "disproportionate," arguing the market underweighted durability and tolerability.

Additional supports include a differentiated safety profile, a breast cancer readout (PIK-101) expected in 2027, anticipated Phase 3 regulatory guidance in early 2027, and roughly $186 million in cash as of the most recent quarter. A clinical-stage valuation reset after the selloff also gives analyst price targets significant headroom.

What Could Prevent the Target From Being Reached

The principal obstacle is binary clinical risk: a disappointing PIK-101 breast cancer readout or unfavorable regulatory feedback would undermine the thesis that PIKTOR is differentiated. The 33% ORR, while within prior guidance, sits broadly in line with emerging ADCs rather than clearly above them, and six patients were excluded from the efficacy analysis.

As a pre-revenue company, FTH carries heavy losses — a quarterly net loss of roughly $16 million and trailing diluted EPS (earnings per share) near -$22.50 — and will likely need additional capital, risking dilution. Broader factors, including biotech risk appetite and interest rates, also influence how richly early-stage pipelines are valued.

Technical Levels and Market Structure

The post-data plunge reset the chart. Intraday support emerged near $10.45, close to the stock's June low around $10; a decisive break below that zone would leave the 52-week low of $7.45 as the next reference. On the upside, the day's high near $16.64 and the prior close near $22 mark the first meaningful resistance levels. The long-term structure remains dominated by the $7.45–$42.14 range, and any sustainable move toward $61 would require a sequence of higher highs well beyond current technical resistance.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, and the targets reviewed here were issued or reaffirmed in late October and November 2026. Investors should watch for the PIK-101 breast cancer readout in 2027, early-2027 Phase 3 regulatory guidance, further details on PIK-201 durability, cash runway updates in quarterly results, and any analyst target revisions as the data set matures.

Using AI Daily Buy/Sell Signals in Practice

In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track momentum shifts in names like FTH without constant manual review. From what I see, these signals help identify when technical conditions align with fundamental catalysts, offering a useful layer for timing entries or exits around binary events.

Final Assessment

The $61 central target reflects a calculated average of recent, verifiable analyst targets, against a latest price near $12.68 — a required move of about 381%, which is very large. Support comes from encouraging Phase 2 efficacy, a manageable safety profile, and a clearly identifiable set of near-term catalysts, while the obstacles are equally clear: binary clinical outcomes, a response rate that does not yet clearly outpace competing ADCs, and ongoing financing needs. With analyst views spanning roughly $40 to $70, the dispersion itself signals real uncertainty about how far the pipeline thesis can run. Whether FTH approaches $61 will depend primarily on the next clinical readouts and regulatory milestones rather than on valuation alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Harry Richardson|Expert

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume